Use of isotretinoin for acne vulgaris

Pediatric Annals

Volumn 38, Issue 6, 2009, Pages 311-320

  Merritt, Bradley ^a   Burkhart, Craig N ^a   Morrell, Dean S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN; RETINOL; DERMATOLOGICAL AGENT;

ABDOMINAL PAIN; ACNE; ACNE VULGARIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APPETITE; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIRTH DEFECT; BONE PAIN; CHOLESTEROL BLOOD LEVEL; DEPRESSION; DERMATITIS; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; DRY SKIN; ENTERITIS; EPISTAXIS; EYE IRRITATION; EYE PAIN; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; HAIR LOSS; HEADACHE; HEALTH CARE COST; HEALTH PROGRAM; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSOMNIA; INTRACRANIAL HYPERTENSION; LEUKOCYTE COUNT; MELANOMA; MUSCLE CRAMP; NAUSEA; PRURITUS; REVIEW; RISK MANAGEMENT; SIDE EFFECT; SUICIDAL IDEATION; SUNBURN; TERATOGENICITY; THIRST; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL; XEROSTOMIA; EVIDENCE BASED MEDICINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; DERMATOLOGIC AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; ISOTRETINOIN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 67849128501     PISSN: 00904481     EISSN: None     Source Type: Journal    
DOI: 10.3928/00904481-20090512-01     Document Type: Review

References (58)

1. Bollag W. The development of retinoids in experimental and clinical oncology and dermatology. J Am Acad Dermatol. 1983;9(5):797-805. (Pubitemid 14230580)
2. Peck GL, Yoder FW. Treatment of lamellar ichthyosis and other keratinizing dermatoses with an oral synthetic retinoid. Lancet. 1976;2(7996):1172-1174.
3. Peck GL, Olsen TG, Yoder FW, et al. Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. N Engl J Med. 1979;300(7):329-333.
4. Peck GL, Olsen TG, Butkus D, et al. Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study. J Am Acad Dermatol. 1982;6(4 Pt 2 Suppl):735-745.
5. The Burden of Skin Diseases 2004 prepared by The Lewin Group, Inc for the SID/AAD. Available at: http://www.sidnet.org/pdfs/B urden%20of%20Skin%20Diseases%20200 4.pdf. Accessed May 13, 2009.
6. Cunliffe WJ. Acne and unemployment. Br J Dermatol. 1986;115(3):386.
7. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998;139(5):846-850.
8. Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol. 1999;140(4):672-676. (Pubitemid 29191387)
9. Kellett SC, Gawkrodger DJ. The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Br J Dermatol. 1999;140(2):273-282.
10. Jones-Caballero M, Chren MM, Soler B, Pedrosa E, Peñas PF. Quality of life in mild to moderate acne: relationship to clinical severity and factors influencing change with treatment. J Eur Acad Dermatol Venereol. 2007;21(2):219-226. (Pubitemid 46128698)
11. Rubinow DR, Peck GL, Squillace KM, Gantt GG. Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinonin. J Am Acad Dermatol. 1987;17(1):25-32.
12. Fried RG, Wechsler A. Psychological problems in the acne patient. Dermatol Ther. 2006;19(4):237-240.
13. Bershad SV. In the clinic. Acne. Ann Intern Med. 2008;149:ITC1-1-ITC1-16.
14. Strauss JS, Krowchukr DP, Leyden JJ, et al; American Academy of Dermatology/ American Academy of Dermatology Association Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56(4):651-663.
15. Strauss JS, Rapini RP, Shalita AR, et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol. 1984;10(3):490-496.
16. Azoulay L, Oraichi D, Bérard A. Isotretinoin therapy and the incidence of acne relapse: a nested case-control study. Br J Dermatol. 2007;157(6):1240-1248. (Pubitemid 350115707)
17. Haryati I, Jacinto SS. Profile of acne patients in the Philippines requiring a second course of oral isotretinoin. Int J Dermatol. 2005;44(12):999-1001. (Pubitemid 43046116)
18. Degitz K, Placzek M, Borelli C, Plewig G. Pathophysiology of acne. J Dtsch Dermatol Ges. 2007;5(4):316-323.
19. Strauss JS, Stranieri AM. Changes in longterm sebum production from isotretinoin therapy. J Am Acad Dermatol. 1982;6(4 Pt 2):751-756.
20. Perry MD, McEvoy GK. Isotretinoin: new therapy for severe acne. Clin Pharm. 1983;2(1):12-19. (Pubitemid 13181541)
21. Weissmann A, Wagner A, Plewig G. Reduction of bacterial skin fl ora during oral treatment of severe acne with 13-cis retinoic acid. Arch Dermatol Res. 1981;270(2):179-183. (Pubitemid 11153499)
22. Zelickson AS, Strauss JS, Mottaz J. Ultrastructural changes in sebaceous glands following treatment of cystic acne with isotretinoin. Am J Dermatopathol. 1986;8(2):139-143. (Pubitemid 17045839)
23. Garcia-Bournissen F, Tsur L, Goldstein LH, et al. Fetal exposure to isotretinoinan international problem. Reprod Toxicol. 2008;25(1):124-128. (Pubitemid 50013715)
24. Sladden MJ, Harman KE. What is the chance of a normal pregnancy in a woman whose fetus has been exposed to isotretinoin? Arch Dermatol. 2007;143(9):1187-1188.
25. Brelsford M, Beute TC. Preventing and managing the side effects of isotretinoin. Semin Cutan Med Surg. 2008;27(3):197-206.
26. Bérard A, Azoulay L, Koren G, Blais L, Perreault S, Oraichi D. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol. 2007;63(2):196-205. (Pubitemid 46072106)
27. Cheetham TC, Wagner RA, Chiu G, Day JM, Yoshinaga MA, Wong L. A risk management program aimed at preventing fetal exposure to isotretinoin: retrospective cohort study. J Am Acad Dermatol. 2006;55(3):442-448. (Pubitemid 44209288)
28. Green J. Babies, blemishes and FDA: A history of Accutane regulation in the United States. Available at http://leda.law.harvard. edu/leda/data/472/ Green.html. Accessed May 13, 2009.
29. Nava-Ocampo AA, Koren G. Human teratogens and evidence-based teratogen risk counseling: the Motherisk approach. Clin Obstet Gynecol. 2007;50(1):123-131. (Pubitemid 46279855)
30. Abroms L, Maibach E, Lyon-Daniel K, Feldman SR. What is the best approach to reducing birth defects associated with isotretinoin? PLoS Med. 2006;3(11):e483
31. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med. 1995;333(2):101-106.
32. Wysowski DK, Swann J, Vega A. Use of isotretinoin (Accutane) in the United States: rapid increase from 1992 through 2000. J Am Acad Dermatol. 2002;46(4):505-509.
33. Mendelsohn AB, Governale L, Trontell A, Seligman P. Changes in isotretinoin prescribing before and after implementation of the System to Manage Accutane Related Teratogenicity (SMART) risk management program. Pharmacoepidemiol Drug Saf. 2005;14(9):615-618. (Pubitemid 41358697)
34. Statement by Janet Woodcock, MD, Director, Center for Drug Evaluation and Research, 2002. Available at: http://www.fda. gov/ola/2002/accutane1211.html. Accessed May 12, 2009.
35. Briefi ng document for iPLEDGE year one update. Available at: http://www.fda.gov/ ohrms/dockets/ac/07/briefi ng/2007-4311b1-02-ipledge.pdf. Accessed May 12, 2009.
36. Dooren JC Restrictions curb use of powerful acne drug. September 12, 2006. Pittsburgh Post Gazette. Available at: http:// www.post-gazette.com/pg/ 06255/721155-114.stm. Accessed May 12, 2009.
37. Dicken CH. Retinoids: a review. J Am Acad Dermatol. 1984;11(4 Pt 1):541-552.
38. Brelsford M, Beute TC. Preventing and managing the side effects of isotretinoin. Semin Cutan Med Surg. 2008;27(3):197-206.
39. Kaymak Y, Ilter N. The results and side effects of systemic isotretinoin treatment in 100 patients with acne vulgaris. Dermatol Nurs. 2006;18(6):576-580.
40. Zane LT, Leyden WA, Marqueling AL, Manos MM. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol. 2006;142(8):1016-1022.
41. DiGiovanna JJ, Sollitto RB, Abangan DL, Steinberg SM, Reynolds JC. Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol. 1995;131(11):1263-1267.
42. DiGiovanna JJ, Langman CB, Tschen EH, et al. Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne. J Am Acad Dermatol. 2004;51(5):709-717.
43. Ling TC, Parkin G, Islam J, Seukeran DC, Cunliffe WJ. What is the cumulative effect of longterm, low-dose isotretinoin on the development of DISH? Br J Dermatol. 2001;144(3):630-632. (Pubitemid 32232030)
44. Fraunfelder FT, Fraunfelder FW, Edwards R. Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol. 2001;132(3):299-305. (Pubitemid 32768596)
45. Mollan SP, Woodcock M, Siddiqi R, Huntbach J, Good P, Scott RA. Does use of isotretinoin rule out a career in fl ying? Br J Ophthalmol. 2006;90(8):957-959. (Pubitemid 44140170)
46. FAA medical exam guidelines. Available at: http://www.faa.gov/about/ office-org/headquarters-offices/avs/offices/aam/ame/guide/app-process/exam-tech/ item40/amd/cutaneous/. Accessed May 13, 2009.
47. Fraunfelder FW, Fraunfelder FT, Corbett JJ. Isotretinoin-associated intracranial hypertension. Ophthalmology. 2004;111(6):1248-1250.
48. Birmaher B, Ryan ND, Williamson DE, et al. Childhood and adolescent depression: a review of the past 10 years. Part 1. J Am Acad Child Adolesc Psychiatry. 1996;35(11):1427-1439. (Pubitemid 26360928)
49. Hoyert DL, Kochanek KD, Murphy SL. Deaths: fi nal data for 1997. Natl Vital Stat Rep. 1999;47(19):1-104.
50. Strahan JE, Raimer S. Isotretinoin and the controversy of psychiatric adverse effects. Int J Dermatol. 2006;45(7):789-799. (Pubitemid 43984385)
51. Danielson R, Bennett K. Suit: drug behind suicide fl ight. St. Petersburg Times. April 17, 2002. Available at: http://www.sptimes.com/2002/04/17/ TampaBay/Suit--Drug-behind-sui.shtml. Accessed May 13, 2009.
52. Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol. 2001;45(4):515-519. (Pubitemid 32917244)
53. Azoulay L, Blais L, Koren G, LeLorier J, Bérard A. Isotretinoin and the risk of depression in patients with acne vulgaris: a case-crossover study. J Clin Psychiatry. 2008;69(4):526-532. (Pubitemid 351792326)
54. Bigby M. Does isotretinoin increase the risk of depression? Arch Dermatol. 2008;144(9):1197-1199.
55. Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg. 2007;26(4):210-220.
56. Voreacos D. Roche to pay $12.9M in Accutane lawsuits. Star-Ledger Business News. November 21, 2008. Available at: http://www.nj.com/ business/ledger/index.ssf?/base/business-10/1227244622115780.xml&coll=1. Accessed May 13, 2009.
57. Reddy D, Siegel CA, Sands BE, Kane S. Possible association between isotretinoin and infl ammatory bowel disease. Am J Gastroenterol. 2006;101(7):1569-1573. (Pubitemid 43980631)
58. Bowser, A. Isotretinoin expensive but costeffective. Dermatology Times. September 1, 2002. Available at: http://dermatologytimes. modernmedicine.com/ dermatologytimes/ Acne/Isotretinoin-expensive-but-cost-effective/ ArticleStandard/Article/detail/33004. Accessed May 13, 2009.